• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过小干扰 RNA 抑制 nNOS 酶可保护 SH-SY5Y 细胞和黑质多巴胺能神经元免受 6-OHDA 损伤。

Suppressing nNOS Enzyme by Small-Interfering RNAs Protects SH-SY5Y Cells and Nigral Dopaminergic Neurons from 6-OHDA Injury.

机构信息

Technology for Gene Therapy Laboratory, Central Institute of Sciences, University of Brasília-FAV, Brasília, DF, 70910-900, Brazil.

Department of Basic and Oral Biology, Dental School, University of São Paulo (USP), Ribeirão Preto, SP, 14040-904, Brazil.

出版信息

Neurotox Res. 2019 Jul;36(1):117-131. doi: 10.1007/s12640-019-00043-9. Epub 2019 Apr 30.

DOI:10.1007/s12640-019-00043-9
PMID:31041676
Abstract

Nitric oxide (NO) has chemical properties that make it uniquely suitable as an intracellular and intercellular messenger. NO is produced by the activity of the enzyme nitric oxide synthases (NOS). There is substantial and mounting evidence that slight abnormalities of NO may underlie a wide range of neurodegenerative disorders. NO participates of the oxidative stress and inflammatory processes that contribute to the progressive dopaminergic loss in Parkinson's disease (PD). The present study aimed to evaluate in vitro and in vivo the effects of neuronal NOS-targeted siRNAs on the injury caused in dopaminergic neurons by the toxin 6-hidroxydopamine (6-OHDA). First, we confirmed (immunohistochemistry and Western blotting) that SH-SY5Y cell lineage expresses the dopaminergic marker tyrosine hydroxylase (TH) and the protein under analysis, neuronal NOS (nNOS). We designed four siRNAs by using the BIOPREDsi algorithm choosing the one providing the highest knockdown of nNOS mRNA in SH-SY5Y cells, as determined by qPCR. siRNA 4400 carried by liposomes was internalized into cells, caused a concentration-dependent knockdown on nNOS, and reduced the toxicity induced by 6-OHDA (p < 0.05). Regarding in vivo action in the dopamine-depleted animals, intra-striatal injection of siRNA 4400 at 4 days prior 6-OHDA produced a decrease in the rotational behavior induced by apomorphine. Finally, siRNA 4400 mitigated the loss of TH(+) cells in substantia nigra dorsal and ventral part. In conclusion, the suppression of nNOS enzyme by targeted siRNAs modified the progressive death of dopaminergic cells induced by 6-OHDA and merits further pre-clinical investigations as a neuroprotective approach for PD.

摘要

一氧化氮 (NO) 具有使其成为细胞内和细胞间信使的独特化学性质。NO 是由酶一氧化氮合酶 (NOS) 的活性产生的。有大量证据表明,NO 的轻微异常可能是多种神经退行性疾病的基础。NO 参与氧化应激和炎症过程,这些过程导致帕金森病 (PD) 中多巴胺能神经元的进行性丧失。本研究旨在评估神经元 NOS 靶向 siRNA 在神经毒素 6-羟多巴胺 (6-OHDA) 引起的多巴胺能神经元损伤中的体外和体内作用。首先,我们通过免疫组织化学和 Western blot 证实 SH-SY5Y 细胞系表达多巴胺能标志物酪氨酸羟化酶 (TH) 和分析蛋白神经元型一氧化氮合酶 (nNOS)。我们使用 BIOPREDsi 算法设计了四个 siRNA,选择通过 qPCR 确定在 SH-SY5Y 细胞中提供 nNOS mRNA 最高敲低的 siRNA。由脂质体携带的 siRNA 4400 被内化到细胞中,引起 nNOS 的浓度依赖性敲低,并降低 6-OHDA 诱导的毒性 (p<0.05)。关于在多巴胺耗竭动物中的体内作用,6-OHDA 前 4 天向纹状体内注射 siRNA 4400 可减少阿扑吗啡诱导的旋转行为。最后,siRNA 4400 减轻了黑质背侧和腹侧部分中 TH(+)细胞的丢失。总之,靶向 siRNA 抑制 nNOS 酶可改变 6-OHDA 诱导的多巴胺能细胞的进行性死亡,值得进一步进行临床前研究,作为 PD 的神经保护方法。

相似文献

1
Suppressing nNOS Enzyme by Small-Interfering RNAs Protects SH-SY5Y Cells and Nigral Dopaminergic Neurons from 6-OHDA Injury.通过小干扰 RNA 抑制 nNOS 酶可保护 SH-SY5Y 细胞和黑质多巴胺能神经元免受 6-OHDA 损伤。
Neurotox Res. 2019 Jul;36(1):117-131. doi: 10.1007/s12640-019-00043-9. Epub 2019 Apr 30.
2
Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.黄芪甲苷对6-羟基多巴胺处理的原代黑质细胞培养物的神经保护作用。
Neurochem Int. 2009 Nov;55(6):414-22. doi: 10.1016/j.neuint.2009.04.012. Epub 2009 May 4.
3
Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis.大鼠黑质致密部微量注射6-羟基多巴胺诱导的胃调节异常由脑-肠轴的改变所决定。
Am J Physiol Gastrointest Liver Physiol. 2014 Nov 15;307(10):G1013-23. doi: 10.1152/ajpgi.00258.2014. Epub 2014 Oct 2.
4
Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine.6-OHDA 损毁大鼠黑质和丘脑底核中 nNOS 表达的改变:左旋多巴和一氧化氮供体吗多明慢性治疗的影响。
Brain Res. 2013 Dec 6;1541:92-105. doi: 10.1016/j.brainres.2013.10.011. Epub 2013 Oct 12.
5
Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.和厚朴酚在逆转帕金森病小鼠模型运动缺陷和神经元变性中的保护和治疗作用。
Pharmacol Rep. 2018 Aug;70(4):668-676. doi: 10.1016/j.pharep.2018.01.003. Epub 2018 Jan 12.
6
A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway.一氧化氮合酶抑制剂可降低6-羟基多巴胺对大鼠黑质纹状体通路中酪氨酸羟化酶和神经元型一氧化氮合酶的影响。
Brain Res. 2008 Apr 8;1203:160-9. doi: 10.1016/j.brainres.2008.01.088. Epub 2008 Feb 13.
7
Moutan Cortex Radicis inhibits the nigrostriatal damage in a 6-OHDA-induced Parkinson's disease model.牡丹皮根抑制 6-OHDA 诱导的帕金森病模型中的黑质纹状体损伤。
Chin J Nat Med. 2018 Jul;16(7):490-498. doi: 10.1016/S1875-5364(18)30084-0.
8
Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.利拉鲁肽(一种胰高血糖素样肽-1(GLP-1)受体激动剂)在大鼠帕金森病部分和完全黑质6-羟基多巴胺损伤模型中的特性研究。
Brain Res. 2016 Sep 1;1646:354-365. doi: 10.1016/j.brainres.2016.05.038. Epub 2016 May 24.
9
Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.富马酸二甲酯通过增强Nrf2活性减轻6-羟基多巴胺诱导的SH-SY5Y细胞和帕金森病动物模型中的神经毒性。
Neuroscience. 2015 Feb 12;286:131-40. doi: 10.1016/j.neuroscience.2014.11.047. Epub 2014 Nov 29.
10
Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.对羟基苯甲酸甲酯可保护 6-羟多巴胺诱导的 SH-SY5Y 细胞毒性,并改善帕金森病小鼠模型的行为损伤。
Neurotoxicology. 2013 Jan;34:25-32. doi: 10.1016/j.neuro.2012.10.003. Epub 2012 Oct 12.

引用本文的文献

1
Nitric Oxide in Parkinson's Disease: The Potential Role of Dietary Nitrate in Enhancing Cognitive and Motor Health via the Nitrate-Nitrite-Nitric Oxide Pathway.帕金森病中的一氧化氮:膳食硝酸盐通过硝酸盐-亚硝酸盐-一氧化氮途径改善认知和运动健康的潜在作用。
Nutrients. 2025 Jan 22;17(3):393. doi: 10.3390/nu17030393.
2
Unraveling Dysregulated Cell Signaling Pathways, Genetic and Epigenetic Mysteries of Parkinson's Disease.解析帕金森病失调的细胞信号通路、遗传和表观遗传之谜。
Mol Neurobiol. 2024 Nov;61(11):8928-8966. doi: 10.1007/s12035-024-04128-1. Epub 2024 Apr 4.
3
The use of nanoparticles in the treatment of infectious diseases and cancer, dental applications and tissue regeneration: a review.

本文引用的文献

1
Therapeutic Oligonucleotides: State of the Art.治疗性寡核苷酸:最新进展。
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:605-630. doi: 10.1146/annurev-pharmtox-010818-021050. Epub 2018 Oct 9.
2
Gene-silencing technology gets first drug approval after 20-year wait.经过20年的等待,基因沉默技术首次获得药物批准。
Nature. 2018 Aug;560(7718):291-292. doi: 10.1038/d41586-018-05867-7.
3
Delivery of miRNA-Targeted Oligonucleotides in the Rat Striatum by Magnetofection with Neuromag.利用 Neuromag 磁转染在大鼠纹状体中递送 miRNA 靶向寡核苷酸。
纳米颗粒在传染病和癌症治疗、牙科应用及组织再生中的应用:综述
Front Med Technol. 2024 Jan 23;5:1330007. doi: 10.3389/fmedt.2023.1330007. eCollection 2023.
4
Role of neuroinflammation in neurodegeneration development.神经炎症在神经退行性变发展中的作用。
Signal Transduct Target Ther. 2023 Jul 12;8(1):267. doi: 10.1038/s41392-023-01486-5.
5
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate.7-硝基吲唑可减少非人类帕金森病灵长类动物的 L-多巴诱导的运动障碍。
Open Biol. 2023 May;13(5):220370. doi: 10.1098/rsob.220370. Epub 2023 May 17.
6
Nitrosative stress in Parkinson's disease.帕金森病中的亚硝化应激
NPJ Parkinsons Dis. 2022 Aug 11;8(1):104. doi: 10.1038/s41531-022-00370-3.
7
Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade.微小RNA-204-5p的表达上调通过靶向DYRK1A介导的凋亡信号级联导致多巴胺能细胞死亡。
Front Cell Neurosci. 2019 Sep 13;13:399. doi: 10.3389/fncel.2019.00399. eCollection 2019.
Molecules. 2018 Jul 23;23(7):1825. doi: 10.3390/molecules23071825.
4
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.用于遗传性转甲状腺素蛋白淀粉样变性的 RNAi 治疗药物 Patisiran
N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153.
5
Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease.聚乙烯亚胺纳米颗粒介导的小干扰RNA递送以降低帕金森病模型中α-突触核蛋白的表达
Mol Ther Nucleic Acids. 2017 Dec 15;9:57-68. doi: 10.1016/j.omtn.2017.08.013. Epub 2017 Aug 30.
6
The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future.帕金森病的 200 年历程:回顾过去,展望未来。
Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S1-S5. doi: 10.1016/j.parkreldis.2017.07.020. Epub 2017 Aug 1.
7
The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.十款基于合成RNA干扰的药物角逐医药市场。
Pharm Res. 2017 Jul;34(7):1339-1363. doi: 10.1007/s11095-017-2134-2. Epub 2017 Apr 7.
8
The chemical evolution of oligonucleotide therapies of clinical utility.具有临床应用价值的寡核苷酸疗法的化学进化
Nat Biotechnol. 2017 Mar;35(3):238-248. doi: 10.1038/nbt.3765. Epub 2017 Feb 27.
9
The SH-SY5Y cell line in Parkinson's disease research: a systematic review.帕金森病研究中的SH-SY5Y细胞系:一项系统综述。
Mol Neurodegener. 2017 Jan 24;12(1):10. doi: 10.1186/s13024-017-0149-0.
10
Inhibition by Multifunctional Magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease Model.载有α-突触核蛋白RNA干扰质粒的多功能磁性纳米颗粒对帕金森病模型的抑制作用
Theranostics. 2017 Jan 1;7(2):344-356. doi: 10.7150/thno.16562. eCollection 2017.